SCHEMBL22979877

SCHEMBL22979877

CCOC(=O)c1cc(Cl)ccc1OC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 2/20 0.46
MAPK1 P28482 1/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
ALOX15 P16050 1/20 0.44
TSHR P16473 2/20 0.44
KDM4E B2RXH2 1/20 0.44
KMT2A Q03164 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.43
LMNA P02545 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
BAZ2A Q9UIF9 1/20 0.43
APP P05067 1/20 0.42
P2RX1 P51575 1/20 0.41
ABCB11 O95342 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR2A P28223 1/20 0.41
PMP22 Q01453 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29648921 1.00 ANO1 (0.46) ANO1MAPK1CYP4F2CYP4A11ALOX15
SCHEMBL22980630 0.89 MAPK1 (0.46) ANO1MAPK1CYP4F2CYP4A11ALOX15
SCHEMBL22979527 0.84 TSHR (0.50) MAPK1CYP4F2CYP4A11TSHRKDM4E
SCHEMBL30843111 0.84 ABL1 (0.51) ANO1KMT2AMRGPRX4LMNAP2RX1
SCHEMBL937129 0.83 LMNA (0.47) MAPK1CYP4F2CYP4A11TSHRKMT2A
SCHEMBL13076753 0.83 LMNA (0.47) MAPK1CYP4F2CYP4A11ALOX15TSHR
SCHEMBL28758200 0.82 ANO1 (0.45) ANO1MAPK1TSHRKDM4EKMT2A
SCHEMBL4364443 0.82 GAA (0.50) MAPK1CYP4F2CYP4A11ALOX15TSHR
SCHEMBL4729820 0.82 LMNA (0.61) MAPK1TSHRKDM4EKMT2ALMNA
SCHEMBL3305731 0.81 MAPK1 (0.42) MAPK1CYP4F2CYP4A11ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 ANO1 3713/4885MAPK1 787/4885CYP4F2 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.